Compare EVH & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVH | CERS |
|---|---|---|
| Founded | 2011 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.8M | 276.0M |
| IPO Year | 2015 | 1996 |
| Metric | EVH | CERS |
|---|---|---|
| Price | $3.03 | $1.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $7.93 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 1.8M |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $907,957,000.00 | $51,326,000.00 |
| Revenue This Year | $33.03 | $20.00 |
| Revenue Next Year | $16.03 | $9.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $2.50 | $1.12 |
| 52 Week High | $11.92 | $2.96 |
| Indicator | EVH | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 31.21 |
| Support Level | $2.53 | $1.27 |
| Resistance Level | $4.20 | $1.72 |
| Average True Range (ATR) | 0.27 | 0.16 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 43.10 | 7.55 |
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.